Clearpoint Neuro, Inc. (CLPT) Stock Price & Analysis
Clearpoint Neuro, Inc. (CLPT) rose 1.57% to USD 13.59 as of June 10, 2026 at 05:03 UTC, according to Nexqual real-time market data.
CLPT last closed at USD 13.38; the session ranged USD 12.82–13.99 on volume of 323,681 shares. Market capitalization is $407.56M, with a 52-week range of USD 8.27–30.1 (NCM). Source: Nexqual, June 10, 2026 at 05:03 UTC.
Key Statistics (as of June 10, 2026 at 05:03 UTC)
| Price | USD 13.59 |
|---|---|
| Change | ▲ 1.57% (up) |
| Previous Close | USD 13.38 |
| Open | USD 13.72 |
| Day Range | USD 12.82 – 13.99 |
| 52-Week Range | USD 8.27 – 30.1 |
| Volume | 323,681 shares |
| Market Cap | $407.56M |
| Exchange | NCM |
Technical Analysis (CLPT)
Nexqual's technical model rates CLPT "STRONG BUY" based on 5 bullish and 0 bearish signals across 123 daily candles, as of June 10, 2026 at 05:03 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.12 (neutral) |
| vs SMA50 | Above (USD 11.16) |
| MACD | 0.55 (positive) |
Analyst Ratings (CLPT)
Wall Street analysts rate CLPT "Strong Buy" based on 3 analysts, with a mean price target of USD 22 (range USD 16–30), per Nexqual as of June 10, 2026 at 05:03 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 22 |
| High Target | USD 30 |
| Low Target | USD 16 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (CLPT)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.29 |
| Revenue Estimate | $12.73M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.32 vs est -0.27 ▼ miss |
| 2025-12-31 | USD -0.27 vs est -0.2 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.2 ▼ miss |
| 2025-06-30 | USD -0.21 vs est -0.2 ▼ miss |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financials & Fundamentals (CLPT)
| Total Revenue | $40.61M |
|---|---|
| Revenue Growth (YoY) | +42.90% |
| Gross Margin | +62.33% |
| Operating Margin | -69.90% |
| Profit Margin | -71.57% |
| ROE | -149.72% |
| Debt / Equity | 337.5 |
| Current Ratio | 5.79 |
| Total Cash | $35.59M |
| Total Debt | $63.59M |
| Free Cash Flow | $-11.63M |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Financial Health Score (CLPT)
Nexqual rates Clearpoint Neuro, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 05:03 UTC.
| Growth | Strong — Revenue +18% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Weak — $36M cash vs $64M debt |
| Cash Flow | Weak — FCF negative: -$12M, burning cash |
| Efficiency | Critical — ROE -150%, ROA -25.0% |
Ownership (CLPT)
| Insider Ownership | +8.45% |
|---|---|
| Institutional Ownership | +50.60% |
| Shares Outstanding | 29.99M |
| Float | 26.27M |
| Short % of Float | +16.37% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
Leadership (CLPT)
Clearpoint Neuro, Inc. is led by Joseph Michael Burnett (age 48), President, CEO & Director, per Nexqual as of June 10, 2026 at 05:03 UTC.
| President, CEO & Director | Joseph Michael Burnett (age 48) |
|---|---|
| Chief Financial Officer | Danilo D'Alessandro (age 40) |
| Chief Operating Officer | Mazin Sabra (age 45) |
| Senior Vice President of Sales & Business Development | Robert C. Korn (age 60) |
| Senior Vice President of Regulatory Affairs | Mary McNamara-Cullinane RAC |
Major Backers & Investors (CLPT)
Notable institutional backers of Clearpoint Neuro, Inc. include MAK Capital One LLC, Lane Generational LLC, Goldman Sachs, according to Nexqual as of June 10, 2026 at 05:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| MAK Capital One LLC | 6.34% |
| Lane Generational LLC | 1.62% |
| Goldman Sachs | 1.55% |
| UBS Group AG | 1.44% |
| Fidelity | 1.4% |
| SG Americas Securities, LLC | 1.24% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.85% |
| Vanguard Group | 9.13% |
| State Street | 2.59% |
| Geode Capital | 2.35% |
Source: Nexqual, June 10, 2026 at 05:03 UTC.
From Clearpoint Neuro, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)
Key Strengths & Strategy (as disclosed to the SEC)
- ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States.
- The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
- It also provides ClearPoint software, which guides the physician in surgical planning, device alignment, navigation to the target, and procedure monitoring; ClearPoint Prism Neuro laser therapy system to necrotize or coagulate soft tissue; and IRRAflow system, an active fluid exchange platform.
- In addition, the company offers consulting services to its pharmaceutical and other medical technology partners, such as benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and translation from the preclinical to the clinical setting.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| TMDX | TransMedics Group, Inc. | USD 74.29 | ▲ 7% |
| HROW | Harrow, Inc. | USD 33.46 | ▲ 0.81% |
| DRIO | DarioHealth Corp. | USD 7.53 | ▲ 0.4% |
| PSNL | Personalis, Inc. | USD 9.75 | ▼ 9.3% |
| PAVM | PAVmed Inc. | USD 4.68 | ▼ 14.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 05:03 UTC. This page is informational and not investment advice.